Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2025-10-23 00:00:00 ET · period of report 2025-10-21 · accession 0001507650-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-10-23 | 2025-10-21 | SMMT | Zanganeh Mahkam | Co-CEO, Dir, 10% | A - Grant | $18.74 | +14.25M | 570.07M | +3% | +$267.00M |
| I | 2025-10-23 | 2025-10-21 | SMMT | Zanganeh Mahkam | Co-CEO, Dir, 10% | P - Purchase | $18.74 | +26.7K | 76.7K | +53% | +$500.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-21 | A | A | 266,808 | $18.74 | 25,724,474 | I By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | — | — | (F1) Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. (F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| 2 | Common | Common Stock | 2025-10-21 | P | A | 26,680 | $18.74 | 76,680 | I Immediate family member | — | — | (F1) Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. (F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| 3 | Common | Common Stock | 2025-10-21 | A | A | 13,980,789 | $18.74 | 570,073,879 | I By Spouse | — | — | (F1) Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. (F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |